Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Site-specific gene expression profiling as a novel strategy for unravelling keloid disease pathobiology.

Jumper N, Hodgkinson T, Paus R, Bayat A.

PLoS One. 2017 Mar 3;12(3):e0172955. doi: 10.1371/journal.pone.0172955. eCollection 2017.

2.

Negative Regulation of Type 2 Immunity.

de Kouchkovsky DA, Ghosh S, Rothlin CV.

Trends Immunol. 2017 Mar;38(3):154-167. doi: 10.1016/j.it.2016.12.002. Epub 2017 Jan 9. Review.

PMID:
28082101
3.

IL-13 is a therapeutic target in radiation lung injury.

Chung SI, Horton JA, Ramalingam TR, White AO, Chung EJ, Hudak KE, Scroggins BT, Arron JR, Wynn TA, Citrin DE.

Sci Rep. 2016 Dec 22;6:39714. doi: 10.1038/srep39714.

4.

Differential effects of peptidoglycan on colorectal tumors and intestinal tissue post-pelvic radiotherapy.

Li G, Wu A, Qi D, Cui F, Zeng Y, Xie F, Wu H, Gu Y, Chen Q, Zhang X.

Oncotarget. 2016 Nov 15;7(46):75685-75697. doi: 10.18632/oncotarget.12353.

5.

IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses.

Lee CM, He CH, Nour AM, Zhou Y, Ma B, Park JW, Kim KH, Dela Cruz C, Sharma L, Nasr ML, Modis Y, Lee CG, Elias JA.

Nat Commun. 2016 Sep 15;7:12752. doi: 10.1038/ncomms12752.

6.

IL-13/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells.

Cao H, Zhang J, Liu H, Wan L, Zhang H, Huang Q, Xu E, Lai M.

Oncotarget. 2016 Sep 20;7(38):61183-61198. doi: 10.18632/oncotarget.11282.

7.

Interleukin-13 Activates Distinct Cellular Pathways Leading to Ductular Reaction, Steatosis, and Fibrosis.

Gieseck RL 3rd, Ramalingam TR, Hart KM, Vannella KM, Cantu DA, Lu WY, Ferreira-González S, Forbes SJ, Vallier L, Wynn TA.

Immunity. 2016 Jul 19;45(1):145-58. doi: 10.1016/j.immuni.2016.06.009. Epub 2016 Jul 12.

8.

IL-17A enhances IL-13 activity by enhancing IL-13-induced signal transducer and activator of transcription 6 activation.

Hall SL, Baker T, Lajoie S, Richgels PK, Yang Y, McAlees JW, van Lier A, Wills-Karp M, Sivaprasad U, Acciani TH, LeCras TD, Myers JB, Kovacic MB, Lewkowich IP.

J Allergy Clin Immunol. 2017 Feb;139(2):462-471.e14. doi: 10.1016/j.jaci.2016.04.037. Epub 2016 Jun 11.

PMID:
27417023
9.

Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-γ.

Ramalingam TR, Gieseck RL, Acciani TH, M Hart K, Cheever AW, Mentink-Kane MM, Vannella KM, Wynn TA.

J Pathol. 2016 Jul;239(3):344-54. doi: 10.1002/path.4733. Epub 2016 Jun 10.

10.

Macrophage and Innate Lymphoid Cell Interplay in the Genesis of Fibrosis.

Hams E, Bermingham R, Fallon PG.

Front Immunol. 2015 Nov 23;6:597. doi: 10.3389/fimmu.2015.00597. eCollection 2015. Review.

11.

Pleiotropic Effects of Immune Responses Explain Variation in the Prevalence of Fibroproliferative Diseases.

Russell SB, Smith JC, Huang M, Trupin JS, Williams SM.

PLoS Genet. 2015 Nov 5;11(11):e1005568. doi: 10.1371/journal.pgen.1005568. eCollection 2015 Nov. Review.

12.

miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program.

Su S, Zhao Q, He C, Huang D, Liu J, Chen F, Chen J, Liao JY, Cui X, Zeng Y, Yao H, Su F, Liu Q, Jiang S, Song E.

Nat Commun. 2015 Oct 5;6:8523. doi: 10.1038/ncomms9523.

13.

The Causal Role of IL-4 and IL-13 in Schistosoma mansoni Pulmonary Hypertension.

Kumar R, Mickael C, Chabon J, Gebreab L, Rutebemberwa A, Garcia AR, Koyanagi DE, Sanders L, Gandjeva A, Kearns MT, Barthel L, Janssen WJ, Mauad T, Bandeira A, Schmidt E, Tuder RM, Graham BB.

Am J Respir Crit Care Med. 2015 Oct 15;192(8):998-1008. doi: 10.1164/rccm.201410-1820OC.

14.

Commentary: IL-4 and IL-13 receptors and signaling.

McCormick SM, Heller NM.

Cytokine. 2015 Sep;75(1):38-50. doi: 10.1016/j.cyto.2015.05.023. Epub 2015 Jul 14.

15.

Chitinase 3-like-1 and its receptors in Hermansky-Pudlak syndrome-associated lung disease.

Zhou Y, He CH, Herzog EL, Peng X, Lee CM, Nguyen TH, Gulati M, Gochuico BR, Gahl WA, Slade ML, Lee CG, Elias JA.

J Clin Invest. 2015 Aug 3;125(8):3178-92. doi: 10.1172/JCI79792. Epub 2015 Jun 29.

16.

Deficiency in Th2 cytokine responses exacerbate orthopoxvirus infection.

Sakala IG, Chaudhri G, Eldi P, Buller RM, Karupiah G.

PLoS One. 2015 Mar 9;10(3):e0118685. doi: 10.1371/journal.pone.0118685. eCollection 2015.

17.

Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair.

Zaiss DM, Gause WC, Osborne LC, Artis D.

Immunity. 2015 Feb 17;42(2):216-26. doi: 10.1016/j.immuni.2015.01.020. Review.

18.

Schistosomiasis-associated pulmonary hypertension.

Papamatheakis DG, Mocumbi AO, Kim NH, Mandel J.

Pulm Circ. 2014 Dec;4(4):596-611. doi: 10.1086/678507. Review.

19.

Incomplete deletion of IL-4Rα by LysM(Cre) reveals distinct subsets of M2 macrophages controlling inflammation and fibrosis in chronic schistosomiasis.

Vannella KM, Barron L, Borthwick LA, Kindrachuk KN, Narasimhan PB, Hart KM, Thompson RW, White S, Cheever AW, Ramalingam TR, Wynn TA.

PLoS Pathog. 2014 Sep 11;10(9):e1004372. doi: 10.1371/journal.ppat.1004372. eCollection 2014 Sep.

20.

Monocyte subsets in schistosomiasis patients with periportal fibrosis.

Fernandes JS, Araujo MI, Lopes DM, de Souza Rda P, Carvalho EM, Cardoso LS.

Mediators Inflamm. 2014;2014:703653. doi: 10.1155/2014/703653. Epub 2014 Mar 13.

Supplemental Content

Support Center